Abstract
The protective effects of rufloxacin againstStaphylococcus aureus-induced infections were compared with those of ciprofloxacin in the granuloma pouch model in the rat. Two strains with different in vitro sensitivity to the drugs were studied. Rufloxacin concentrations persisted longer than ciprofloxacin in the exudate in the pouch cavity and were about eight times higher. Equal doses of rufloxacin and ciprofloxacin had similar antibacterial activities. However, rufloxacin inhibitedStaphylococcus aureus bacterial growth significantly longer than did ciprofloxacin.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Literature Cited
Arko JR, Balows A (1986) Animal models of experimental gonococcal infection. In: Zak O, Sande MA (eds) Experimental models in antimicrobial chemotherapy, vol. 1. London: Academic Press, pp 355–369
Bartlett MS (1947) The use of transformations. Biometrics 3:39–52
Cecchetti V, Fravolini A, Fringuelli R, Mascellani G, Pagella PG, Palmioli M, Segre G, Terni P (1987) Quinolone-carboxylic acids. 2. Synthesis and anti bacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido [1, 2, 3-de] [1, 4] benzothiazine-6-carboxylic acids. J Med Chem 30:465–473
Dalhoff A (1986) The granuloma pouch. In: Zak O, Sande MA (eds) Experimental models in antimicrobial chemotherapy, vol 1. London: Academic Press, pp 123–137
Dirksen MSC, Jol C, Pahlmann W, Bach D, Boerema HBJ (1991) Rufloxacin: penetration in human tissue. J Chemother Suppl. 4:258–259
Fantin B, Leggett J, Ebert S, Craigwa (1991) Correlation between in vitro and in vivo activity of antimicrobial agents against Gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother 35:1413–1422
Frimodt-Moller N, Thomsen VF (1987) The pneumococcus and mouse-protection test: correlation of in vitro and in vivo activity for beta-lactam antibiotics, vancomycin, erytromycin, and gentamicin. Acta Pathol Microbiol Immunol Scand Sect B 95:159–165
Imbimbo BP, Broccali GP, Cesana M, Crema F, Parrinello Attardo G (1991) Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers. Antimicrob Agents Chemother 35:390–393
McCabe WR, Treadwell TL (1986) In vitro susceptibility tests: correlations between sensitivity testing and clinical outcome in infected patients. In: Lorian V (ed) Antibiotics in laboratory medicine. Baltimore: The Williams and Wilkins Co., pp 925–936
NWA STATPAK Multi-function Statistics Library. Version 3.1. Northwest Analytical, Inc., Portland, Oregon
Ravizzola G, Pinsi G, Pirali F, Colombrita D, Foresti I, Peroni L, Turano A (1989) Rufloxacin (MF 934): in vitro and in vivo antibacterial activity. Drugs Exptl Clin Res XV:11–15
Segre G, Cerretani D, Cerri D, Moltoni L (1988) A new tricyclic fluoroquinolone, rufloxacin (MF 934), with interesting antibacterial and pharmacokinetic characteristics. Drugs Exptl Clin Res XIV:747–754
Zak O, O'Reilly T (1991) Animal models in the evaluation of antimicrobial agents. Antimicrob Agents Chemother 35:1527–1531
Zak O, Sande MA (1982) Correlation of in vitro antimicrobial activity of antibiotics with results of treatment in experimental animal models and human infection. In: Sabath LD (ed) Action of antibiotics in patients. Bern, Switzerland: Hans Huber Publishers, pp 55–56
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ravizzola, G., Pinsi, G., Cesana, M. et al. Antibacterial activity of rufloxacin in theStaphylococcus aureus rat granuloma pouch model. Current Microbiology 24, 349–353 (1992). https://doi.org/10.1007/BF01571106
Issue Date:
DOI: https://doi.org/10.1007/BF01571106